Results 191 to 200 of about 9,833 (206)

Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes

Journal of Clinical Endocrinology and Metabolism, 2009
Margaretha Persson, Bo Ahrén
exaly  

Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes

Journal of Clinical Endocrinology and Metabolism, 2005
exaly  

Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

Diabetes, Obesity and Metabolism, 2009
exaly  

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study

Diabetes, Obesity and Metabolism, 2007
exaly  

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes

Diabetes, Obesity and Metabolism, 2007
exaly  

Vildagliptin

Reactions Weekly, 2015
openaire   +1 more source

Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study

Diabetes, Obesity and Metabolism, 2010
exaly  

Vildagliptin

Reactions Weekly
openaire   +1 more source

Efficacy and Safety of Vildagliptin in New-Onset Diabetes After Kidney Transplantation—A Randomized, Double-Blind, Placebo-Controlled Trial

American Journal of Transplantation, 2014
exaly  

Comparison between vildagliptin and metformin to sustain reductions in HbA1cover 1 year in drug-naïve patients with Type 2 diabetes

Diabetic Medicine, 2007
exaly